Author:
Nozza S.,Galli L.,Antinori A.,Chiappetta S.,Mazzotta F.,Zaccarelli M.,Ottou S.,De Battista D.,Pogliaghi M.,Di Pietro M.,Malnati M.,Ripa M.,Bonora S.,Lazzarin A.
Subject
Infectious Diseases,Microbiology (medical),General Medicine
Reference27 articles.
1. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents;Panel on Antiretroviral Guidelines for Adults and Adolescents,2012
2. Lopinavir/ritonavir combined with raltegravi er tenofovir/emtricitabine in antiretroviral-naive subjects: 96-weeks results of the PROGRESS study;Reynes;AIDS Res Hum Retroviruses,2013
3. Dual therapy with lopinavir/ritonavir (LPV/r) and lamivudine (3TC) is non-inferior to standard triple drug therapy in naive HIV-1 infected subjects: 48-week results of the GARDEL study;Cahn,2013
4. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial;Raffi;Lancet,2014
5. Five-year safety evaluation of maraviroc in HIV-1-infected, treatment-experienced patients;Gulick;J Acquir Immune Defic Syndr,2014
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献